|
| ||
| High viremia pre-meds effect on cd4 rise after treatment Aug 16, 2009 Hi, Dr. Holodniy. I recently started medication (atripla), after a consistently very high viral load (500k 800k) and all over the map cd4 numbers (250-700) coupled with a constantly decreasing cd4 percentage. Most probable date of infection is a year ago. 4 weeks after starting meds these were my numbers: CD4 600, 19% (up from 350, 13%), VL 2.91 log (down from 5.89 log). I know the results are very encouraging, and was wondering if they are predictive of a good treatment outcome and whether they are consistent with the probable date of infection or such a cd4 rise is just something that is usually seen in patients that start meds with a high viremia. Thanks a lot. |
|||||||||||
|
|
Response from Dr. Holodniy
There is some data to indicate that your response after 4 weeks is predictive of long term response to treatment. But, this has not been completely worked out. I am not aware of CD4 trajectory being predictive of the date of when infection occurred. Your absolute CD4 count increase is definitely greater than we normally see at one month, but not necessarily the percentage. In addition, the CD4 percent is still low with respect to absolute count. In other words, someone without HIV infection and who has a CD4 count of 600 would normally have a CD4 percent of 30-50%. | ||||||||||
Get Email Notifications When This Forum Updates or Subscribe With RSS
|
|||||||||||
Q&A TERMS OF USE
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.
Review our complete terms of use and copyright notice.







